Audrey Simonaggio

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Audrey Simonaggio, Jean‐Marie Michot, Anne Laure Voisin et al. · JAMA Oncology · 2019 · 354 citations · Full text

The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study

Jean‐Marie Michot, Ariane Lappara, Jérôme Le Pavec et al. · European Journal of Cancer · 2020 · 59 citations

Clinical Immunology, Immunodeficiencies, Collaborative Management +11

Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab

Audrey Simonaggio, Réza Elaidi, Laure Fournier et al. · Cancer Immunology Immunotherapy · 2020 · 54 citations · Full text

Cancer Immunosurveillance, Genitourinary Cancer, Medicine +6

BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer

Nicolas Epaillard, Audrey Simonaggio, Réza Elaidi et al. · Bulletin du Cancer · 2020 · 41 citations

Urology, Genitourinary Cancer, Medicine +5

Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit

Adrien Joseph, Audrey Simonaggio, Annabelle Stoclin et al. · Annals of Intensive Care · 2020 · 39 citations · Full text